The sequential recovery in gross margin from 20.7% in 2026Q1 to 31.2% in 2026Q3 suggests a rebound in pricing or mix, yet the TTM operating margin of -42.5% is overwhelmed by non-cash charges, as evidenced by the 2025Q3 net margin of -160.3%. Investors should focus on adjusted operating margin, which appears to be in the high single digits based on 2026Q3's 8.2%, to gauge true earning power. The gap between reported and adjusted margins warrants close monitoring, as the sustainability of the recovery depends on whether the impairment charges are truly one-time.

The ten-quarter trend shows ROIC oscillating between -1.1% and 1.4%, with the 2025Q3 impairment quarter dragging the average down. The 2026Q3 ROIC of 1.0% is a recovery but still inadequate, suggesting that the company is not yet generating economic profits. The depressed equity base, down to $1.9B from $3.0B in 2024Q2, inflates ROE relative to what it would be on a normalized basis, but even so, ROE of 0.9% in 2026Q3 indicates minimal return for shareholders. The key driver is margin normalization; if adjusted operating margins sustain in the high single digits, ROIC could approach mid-single digits, but this remains contingent on the absence of further impairments.

The CCC has trended upward over the past ten quarters, with DIO increasing from 123 days in 2024Q2 to 133 days in 2026Q3, while DSO and DPO have remained relatively stable. This suggests that inventory management has become less efficient, possibly due to deliberate stockpiling of raw materials or slower demand in certain segments. The company's ability to hold inventory is supported by a strong current ratio of 3.05, but the lengthening cycle ties up cash and may signal a need for working capital discipline. Investors should monitor whether DIO reverts to historical levels as demand normalizes.

The increase in D/E is largely a function of equity compression from impairments, not a build-up of debt, as total debt has remained flat at $1.5B. Interest coverage of 5.54x in 2026Q3 is a recovery from the near-zero levels in 2026Q1, suggesting that operating earnings are sufficient to cover interest expenses. However, the D/EBITDA ratio of 16.58x is elevated, reflecting the depressed EBITDA due to impairments; on a normalized basis, this would be lower. The company's cash balance of $440M provides a buffer, but the high D/EBITDA warrants monitoring if impairments recur.

The quick ratio of 1.89 in 2026Q3 is also strong, suggesting that even without selling inventory, the company can cover its short-term obligations. The cash build is likely a result of divestiture proceeds and strong free cash flow, which reached $102M in 2026Q3. This liquidity provides flexibility for M&A or debt reduction, but it also depresses returns on assets and equity. Under a severe stress scenario, the current ratio would likely remain above 2.0, given the defensive nature of the Life Sciences segment, but the high inventory levels could become a drag if demand falters.